Source: Virtual Congress 2021 – COVID - 19 treatments



Rating:

Share or cite this content

Citations should be made in the following way:
V. Gaynitdinova (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), Z. Merzhoeva (Moscow, Russian Federation), G. Nuralieva (Moscow, Russian Federation). N-acetylcysteine (NAC) in the complex treatment of COVID-associated pneumonia. 3669

Member's Comments

No comment yet.

Related content which might interest you: Four weeks of treatment with n-acetyl cysteine (NAC) (1200mg/day) reduces lung oxidative stress and improves lung function in moderate-to-severe COPD subjects Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Homogenisation of induced sputum with N-acetyl-L-cysteine (NAC) is protective for sputum cells Source: Eur Respir J 2003; 22: Suppl. 45, 292s Year: 2003 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Effect of benzylpenicillin-ciprofloxacin vs. ceftriaxon-ciprofloxacin in treatment of massive pneumonia (CAP-community acquired pneumonia) Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis Source: International Congress 2019 – Treatment of airway diseases in primary care Year: 2019 IFIGENIA (idiopathic pulmonary fibrosis international group exploring NAC I annual): effects of N-acetylcysteine (NAC) on lung function and gas exchange in IPF pati Source: Eur Respir J 2004; 24: Suppl. 48, 668s Year: 2004 Bus drivers supplemented with the anti-oxidant, N-acetyl cysteine (NAC) for 4 weeks show reduced lung oxidative stress and improved lung function Source: Annual Congress 2007 - Acute and chronic effects of air pollution Year: 2007 Mn-superoxide dismutase (Mn-SOD) is upregulated by N-acetylcysteine (NAC) administration in normal and septic rat diaphragms Source: Eur Respir J 2004; 24: Suppl. 48, 333s Year: 2004 The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 713s Year: 2004 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Reduction of oxidative stress in successfully treated patients with community acquired pneumonia (CAP), as measured by redox status of coenzyme Q10 (%CoQ-10) Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Effectiveness of N-acetyl cyctein (NAC) to reduce cough when used together with other over-the-counter (OTC) in common cold (a preliminary study) Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 805s Year: 2006 Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 PIVOT trial (pneumonia intravenous versus oral treatment) Source: Eur Respir J 2003; 22: Suppl. 45, 141s Year: 2003 The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 The effect of erythropoietin (EPO) on cyclooxygenase-2 (COX-2) and cytochrome-c (CYT-c) in the bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Efficacy of combined therapy in severe community-acquired pneumonia (CAP) with efferent detoxication methods (EDM) vs. standard therapy by antibiotics (STA) Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005